US · VNDA · BIOTECHNOLOGY
Vanda Pharmaceuticals Inc. (VNDA) intrinsic value and stock valuation
$3.45as of 2026-11-21 · Mkt cap 306.09M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Vanda Pharmaceuticals Inc. DCF and intrinsic value
InvestorsCraft values VNDA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from VNDA’s statements →
Vanda Pharmaceuticals Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Achieve Life Sciences, Inc. (ACHV) $6.78
- Allogene Therapeutics, Inc. (ALLO) $0.63
- Atea Pharmaceuticals, Inc. (AVIR) $3.96
- Sagimet Biosciences Inc. (SGMT) $9.08
- Entrada Therapeutics, Inc. (TRDA) $4.35
- Capricor Therapeutics, Inc. (CAPR) $7.59
- Voyager Therapeutics, Inc. (VYGR) $1.53
- Arcturus Therapeutics Holdings Inc. (ARCT) $7.45
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M | $268.7M |
| Operating income | -$-151.17M | -$-40.66M | -$-13.95M | $6.33M | $42.2M |
| Net income | -$-220.47M | -$-18.9M | $2.51M | $6.28M | $33.2M |
| EPSd | -$-3.74M | -$-325.02K | $43.6K | $110.2K | $582.4K |
| Operating cash flow | -$-109.44M | -$-15.76M | $12.8M | $32M | $64.2M |
| Capital expenditure | -$-1M | -$-490K | -$-380K | -$-680K | -$-550K |
| Free cash flow | -$-110.44M | -$-16.25M | $12.4M | $31.3M | $63.7M |
| Total assets | $489M | $656.2M | $648.4M | $634.3M | $593.8M |
| Total debt | $12.6M | $12.4M | $9.4M | $11.1M | $12.4M |
| Net debt | -$-72.23M | -$-89.96M | -$-126.42M | -$-123.89M | -$-39.7M |
| Total equity | $327.2M | $538.6M | $544.9M | $527.2M | $504.9M |
| Cash and short-term investments | $263.9M | $374.6M | $388.3M | $466.9M | $432.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M | $268.7M |
| Cost of revenue | $13M | $11.3M | $14.8M | $24.3M | $25.6M |
| Gross profit | $203.1M | $187.5M | $177.8M | $230.1M | $243.1M |
| Research and development expenses | $109.3M | $74.4M | $76.8M | $85.8M | $75.4M |
| Selling, general and administrative expenses | $238M | $146.4M | $112.9M | $136.5M | $124.1M |
| Other expenses | $7.01M | $7.27M | $2.09M | $1.52M | $1.48M |
| Operating expenses | $354.2M | $228.1M | $191.8M | $223.8M | $200.9M |
| Cost and expenses | $367.3M | $239.4M | $206.6M | $248.1M | $226.5M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $200K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $11.9M | $8.13M | $3.01M | $2.73M | $2.84M |
| Ebitda | -$-126.73M | -$-14.79M | $9.35M | $14M | $45.2M |
| Operating income | -$-151.17M | -$-40.66M | -$-13.95M | $6.33M | $42.2M |
| Total other income/expenses, net | $12.5M | $17.7M | $20.3M | $4.97M | $200K |
| Income before tax | -$-138.65M | -$-22.92M | $6.34M | $11.3M | $42.4M |
| Income tax expense | $81.8M | -$-4.02M | $3.83M | $5.03M | $9.21M |
| Net income | -$-220.47M | -$-18.9M | $2.51M | $6.28M | $33.2M |
| Weighted average shares outstanding | $58.9M | $58.2M | $57.4M | $56.5M | $55.6M |
| Weighted average diluted shares outstanding | $58.9M | $58.2M | $57.6M | $57M | $56.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $263.9M | $374.6M | $388.3M | $466.9M | $432.8M |
| Net receivables | $54.6M | $47.1M | $34.2M | $33.5M | $32.5M |
| Inventory | $1.85M | $1.73M | $1.36M | $1.19M | $1.02M |
| Total current assets | $347.3M | $438.9M | $433M | $519.3M | $478.3M |
| Property, plant and equipment, net | $13.5M | $12.7M | $9.14M | $11M | $12.4M |
| Goodwill and intangible assets | $117.1M | $114.1M | $121.4M | $18.6M | $20.1M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $141.7M | $217.3M | $215.5M | $115M | $115.5M |
| Total assets | $489M | $656.2M | $648.4M | $634.3M | $593.8M |
| Accounts payable | $4.94M | $3.5M | $7.14M | $12.7M | $930K |
| Short-term debt | $5.55M | $4.27M | $2.4M | $2.33M | $2.31M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $145.2M | $100M | $87.7M | $91.4M | $74.4M |
| Long-term debt | $7.07M | $8.09M | $7.01M | $8.81M | $10.1M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $16.6M | $17.7M | $15.8M | $15.6M | $14.5M |
| Capital lease obligations | $12.6M | $12.4M | $9.4M | $11.1M | $12.4M |
| Total liabilities | $161.8M | $117.7M | $103.5M | $107.1M | $88.9M |
| Common stock | $60K | $60K | $60K | $60K | $60K |
| Retained earnings | -$-394.77M | -$-174.29M | -$-155.39M | -$-157.9M | -$-164.18M |
| Accumulated other comprehensive income (loss) | $630K | $70K | -$-30K | -$-1.19M | -$-170K |
| Total equity | $327.2M | $538.6M | $544.9M | $527.2M | $504.9M |
| Total investments | $179M | $272.3M | $252.4M | $331.8M | $380.7M |
| Total debt | $12.6M | $12.4M | $9.4M | $11.1M | $12.4M |
| Net debt | -$-72.23M | -$-89.96M | -$-126.42M | -$-123.89M | -$-39.7M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-220.47M | -$-18.9M | $2.51M | $6.28M | $33.2M |
| Depreciation and amortization | -$-950K | $8.13M | $3.01M | $2.73M | $2.84M |
| Stock-based compensation | $9.47M | $12.4M | $14M | $16.3M | $15.4M |
| Change in working capital | $8.31M | -$-6.56M | -$-750K | $6.07M | $2.74M |
| Accounts receivable | -$-7.46M | -$-13.01M | -$-710K | -$-1.09M | -$-2.47M |
| Inventory | -$-3.47M | -$-30K | -$-770K | -$-4.48M | -$-2.23M |
| Accounts payable | $15.8M | $1.71M | -$-10.98M | $11.8M | $3.04M |
| Net cash provided by operating activities | -$-109.44M | -$-15.76M | $12.8M | $32M | $64.2M |
| Investments in property, plant and equipment | -$-1M | -$-490K | -$-380K | -$-680K | -$-550K |
| Acquisitions, net | $0.00 | -$-4.23M | -$-100.67M | $0.00 | $0.00 |
| Net cash used for investing activities | $94.9M | -$-17.43M | -$-12.06M | $49.9M | -$-76.7M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $730K | $3.55M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-2.91M | -$-150K | $0.00 | $730K | $3.55M |
| Net change in cash | -$-17.36M | -$-33.51M | $790K | $83M | -$-9.02M |
| Cash at end of period | $85.3M | $102.8M | $136.3M | $135M | $52.1M |
| Operating cash flow | -$-109.44M | -$-15.76M | $12.8M | $32M | $64.2M |
| Capital expenditure | -$-1M | -$-490K | -$-380K | -$-680K | -$-550K |
| Free cash flow | -$-110.44M | -$-16.25M | $12.4M | $31.3M | $63.7M |
Line items
Line items
Line items
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
- CEO
- Mihael H. Polymeropoulos
- Employees
- 533
- Beta
- 0.60
Included in
Explore
Frequently asked questions
What is the intrinsic value of Vanda Pharmaceuticals Inc. (VNDA)?
Vanda Pharmaceuticals Inc. (VNDA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is VNDA undervalued?
VNDA trades at a price of $3.45 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.